AVLN (Avalyn Pharma) EV-to-EBITDA: (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVLN Avalyn Pharma Inc AVLN
11 GF Score
Price $28.50
View Full Analysis

What is Avalyn Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Avalyn Pharma's enterprise value is $1,156.77 Mil. Avalyn Pharma does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Avalyn Pharma's EV-to-EBITDA at this moment.

The historical rank and industry rank for Avalyn Pharma's EV-to-EBITDA or its related term are showing as below:

AVLN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.08   Med: 0   Max: 0
Current: -12.68
AVLN's EV-to-EBITDA is ranked worse than
100% of 416 companies
in the Biotechnology industry
Industry Median: 11.9 vs AVLN: -12.68

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2026-08-03), Avalyn Pharma's stock price is $28.50. Avalyn Pharma does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Avalyn Pharma's PE Ratio (TTM) at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

Avalyn Pharma  (NAS:AVLN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Avalyn Pharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=28.50/
=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Avalyn Pharma EV-to-EBITDA Related Terms

Avalyn Pharma EV-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Avalyn Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalyn Pharma EV-to-EBITDA Chart

Avalyn Pharma Annual Data
Trend Dec24 Dec25
EV-to-EBITDA
0.00 0.00

Avalyn Pharma Semi-Annual Data
Dec24 Dec25
EV-to-EBITDA 0.00 0.00

AVLN vs TRAX, IMTX, ARDX: EV-to-EBITDA Comparison

For the Biotechnology subindustry, Avalyn Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avalyn Pharma EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalyn Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Avalyn Pharma's EV-to-EBITDA falls into.


AVLN
11GF Score
Avalyn Pharma Inc AVLN
EV-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalyn Pharma EV-to-EBITDA Calculation

Avalyn Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1156.774/
=

Avalyn Pharma Business Description

Address 105 W First Street, Boston, MA, USA, 02127
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score

Get the complete analysis for AVLN

EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.50
Price